Skip to main content

ESWI | VIRTUAL | December 2020

By

ESWI VIRTUAL | December 2020 In Vitro Potency and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Highly Pathogenic Avian Influenza (HPAI) [139] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, by Multiple Dosing Routes Against Influenza A (H1N1), and Activity Against Oseltamivir-Resistant Isolates in Lethal Mouse Models [159] Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains [269]

Read More

ESICM LIVES | VIRTUAL | December 2020

By

ESICM LIVES VIRTUAL | December 2020 Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin: Outcomes by ICU Status and APACHE II Score Analysis of Outcomes by Geographic Region of Enrollment in STRIVE, the Phase 2 of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis (IC) [encore] Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive…

Read More

IDWeek | VIRTUAL | October 2020

By

IDWeek VIRTUAL | October 2020 Efficacy of CD377, a Novel Antiviral Fc-conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models [159] CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models [162] Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models [1276] New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single [1283]

Read More

IDWeek | VIRTUAL | October 2020

By

IDWeek VIRTUAL | October 2020 Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin [637] Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations [1174] Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive…

Read More

ACCP | VIRTUAL | October 2020

By

ACCP VIRTUAL | October 2020 Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations [55655-Encore] Pharmacoepidemiologic Evaluation of Echinocandin Use [55660-Encore]

Read More

ECCMID | Abstract Book | April 2020

By

ECCMID Abstract Book | April 2020 Preclinical Efficacy, Pharmacokinetics, and Safety of CD377, a Novel Antiviral Fc-Conjugate Against Influenza [Abstract 5126] CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Superior Reduction of Viral Burden and Cytokine Levels Compared to Oseltamivir in a Lethal Mouse Model of Influenza A (H1N1) Infection [Abstract 8839] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Seasonal Influenza in Lethal Mouse Models [Abstract 5793] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Influenza…

Read More